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SUMMARY 
Longitudinal designs are often used for studying the natural history of diseases. Data sets typically consist of 
short series of repeated measures on prevalent cases. We propose a growth model approach to the analysis of 
follow-up data to describe functional decline and associated risk factors in disease progression. We illustrate 
the model with an application to longitudinal data that describe the time-evolution of cognitive decline in 
a cohort of patients with Alzheimer’s disease. 
1.  INTRODUCTION 
Better understanding of the course of disease progression is important. It is essential for clinicians, 
as well as patients and their families, to have accurate prognostic information. Natural history 
studies are conducted to evaluate progressive disorders and investigate patterns of functional 
decline, time to certain endpoints such as severe functional deficit, nursing home or death, and 
potential predictors of rapid progression. 
It is known that linear models are not sufficient to portray functional decline in disease 
progression. Non-linear models may be more appropriate, and deserve more consideration. For 
example, cognitive deficits in Alzheimer’s disease typically begin with memory disturbances and 
progress to a point where no abilities are spared. To  describe the pattern of decline, Brooks et al.’ 
proposed a trilinear model with an initial period of stability before detectable decline on 
a cognitive test score, a period of decline, and a final period of stability with no further detectable 
decline. Morris and his colleagues’ also showed that the rate of change of test scores varied with 
level of cognitive impairment of the patients. These observations suggest the study of a family of 
non-linear models. Non-linear growth models, often characterized by S-shape curves, are well 
known and have had wide use in many fields such as biology, chemistry, economics and medical 
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research. When patients’ test scores, measured over time, show a pattern of S-shape decline, the fit 
of a proper growth model to the longitudinal data may help to describe and predict disease 
progression. With such a model, we can identify a typical rapid progression and can easily 
estimate the time to reach a specific value of the test score. 
In a longitudinal study design, it is common among subjects recruited in a prevalent cohort 
that they are at different stages of their disease. They are then examined regularly over the follow- 
up period. The longitudinal data can contain many short series of functional measures, since 
a number of subjects may be examined only for few visits. Non-linear curve fitting of this kind of 
data can be complicated, especially when the time of disease onset is unclear. 
The purpose of this paper is to extend non-linear growth models3 so that we can use them to 
characterize various shapes of functional decline in disease progression as well as to explore 
effects of possible risk factors on the functional decline pattern. The method described in 
Section 2 applies to data from a prevalent cohort where subjects’ disease onset times are unclear. 
Section 3 presents an application of the method followed by a discussion in Section 4. 
2. METHOD 
2.1. Basic model 
Suppose that Y ( T )  is a stochastic process that takes values in R + ,  and measures occur at time 
T = to,  . . . , t, with equal time intervals such that t k  + - tk = c for all k. Here c is a known 
constant. Let Y k  = Y(tk) and Ak = Yk+l - Yk denote the difference between two consecutive 
measures, k = 0, 1, ... ,n. We specify our model by the first two conditional moments: 
var(Akl Y o ,  ... , Yk) = T (2) 
where G(  .) is a differentiable function and 8 and z are unknown parameters. z is a positive 
constant, while 8 can be a vector that determines the shape of the time series {E( Yk+ I Yk) }  
generated by the model. 
Growth models are popular in describing S-shaped growth. They can be specified by a differen- 
tial equation that assumes that the growth rate, derivative of size, is proportional to the present 
size and the future amount of growth. A solution of a specific differential equation is a function of 
time and usually is a non-linear curve. Examples include logistic models, Gompertz models and 
monomolecular models, that we can unify by Von Bertalanffy’s model3, 
y(t) = - (1 - m)exp( - B(t - u)))l’(i-m) if m z 1 
= a exp( - exp( - B(t - u)) )  i f m = 1  
or 
When B > 0, y ( t )  increases with t; and when j3 < 0, y(t) decreases with t. Figure 1 shows some of 
the curves with a = 2 and B = 1 for various m and u. m = 0 produces a monomolecular curve, 
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m = 1 a Gompertz curve, and m = 2 a logistic curve. By assuming that the observed data yi on 
time t i ,  i = 1, ... ,n, are uncorrelated and that 
Yi = y(ti) + Ei  
with E ( E ~ )  = 0 and var(Ei) = c2, we can use conventional non-linear curve fitting procedures to fit 
the growth curve specified by the time function y ( t )  to the data (yi, ti) with t i  known. 
In a prevalent cohort, repeated measures occur regularly over the follow-up period, but the 
follow-up time may not relate consistently to the time since disease onset, and the time since 
disease onset is often hard to estimate precisely. In this case, we cannot directly apply conven- 
tional non-linear curve fitting procedures, and it can be very complicated to fit a non-linear curve 
of the explicit time function. 
In developing an alternative method for analysing this type of data, we note that with subjects 
examined at a constant time interval, we can interpret the difference between functional measures 
at two consecutive visits as the rate of change over the period, and that may depend on the value 
of a previous functional measure. Secondly, when we replace the differential equation of a growth 
curve with a difference equation, we can also generate non-linear curves. Furthermore, the 
differential or difference equation does not involve a time variable directly. To use a difference 
equation, we require equal length time intervals. This is typically feasible in a follow-up study. 
To specify the function G( .) in (l), we adopt a form similar to Von Bertalanffy’s model3 
= B ( Y k  - ao) (log(al) - bg(Yk - ao)) if m = 1 (3) 
where B = (ao, al, B). Note that G(Yk) = 0 at Y k  = a. or Y k  = a. + al, indicating no change at 
that point. When m > 0, Y k  may take on a value between a. and a. + al. In this case, we can view 
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uo and go + ctl as possible 'bounds' that Y k  approaches, the average conditional change E(Akl Y k )  
vanishes. The parameter fi  characterizes dynamic change, and its sign determines the direction of 
the average conditional change. The power parameter rn indicates various models. For rn = 0, 
E(Ak1 Yk) = B(ao + a1 - Yk), corresponding to a monomolecular model with only one bound. 
When Y (T)  is a Gaussian process, it is an autoregression model (AR-l), since we can rewrite (1) as 
(P/o!l)(Yk - c10) (ao + a1 - Yk), corresponding to a logistic model. While m --f 1, we have 
.!?(A," Y k )  = / ? (Yk  - a0) log(al/(Yk - u0)), corresponding to a Gompertz model. The parameter 
rn can take other values as well. 
When m > 0, there exists a point Y, where the rate of change is at its maximum, such that 
dG(Y)/dY = 0 at Y = Y,. Solving the equation, we have 
E(Yk+11 Y k )  = o! + B*(Yk - a) with o! = /?(a0 + M i )  and B* = 1 - /J. When m = 2, E(AkI Y k )  = 
1 K - m )  if , + 1 Y, = a. + alrn 
= a. + a le- '  i f m = l .  (4) 
2.2. Estimation 
Let yi = ( Y ~ , ~ ,  ... , yi,ni) denote a series of functional measures for the ith subject in the follow-up 
study. It is the ith realization of the process Y(T) with T i €  {ti,k}, t i ,k+l  - t i , k  = c, k = 
0,1, ... ,ni - 1, where c is a known constant, but we cannot always observe ti,o. Then we can 
pose that yis are independent and Uy=l(ti,O, ti ni) covers the range of T. The residuals, 
ri,k = Ai,k  - E(Ai,klYi,k), are uncorrelated and thus we have 
obtain Ai = (Ai.0, . . . , Ai,ni-  1) Such that A i , k  = yi,k+ 1 - Yi,k, k = 0, .. . , ni - 1; i = 1, . . . , N .  SUP- 
0 i # j o r k # h  
t i = j  and k = h .  E(ri,k r j , h )  = 
Following Godambe," Zeger and Qaqish,' we adopt a quasi-likelihood approach to estimate the 
model parameters. The estimating functions for 8 and m take the form 
We can obtain consistent estimates of 8 and in by solving equations S ,  = 0 and S 2  = 0 
simultaneously. Note that since in (2) var(Ai,,( Yi ,k)  is a constant, we can exclude it from (6) and (7) 
when solving the equations. 
When a0 is known, taking Zi,k = yi,k - ao, Ai,k  is unchanged because Z i , k + l  - Zi,k = 
yi,k+l - yi,k. E(Ai,kIzi,k) is a linear function of Zi,k and ZTk,  or a linear function of zi,k and 
Zi,k log(zi,k), since for any specific m, 
i f r n # l  
= filOg(o!l)zi,k - BZi,klog(zi,k) = afZi,k + P*zi,klog(zi,k) if m = 1. 
Here 8* = (a:, p*) has a one to one correspondence to 8 = (a,, fi). Solving the equation S, = 0 
may actually produce a least squares estimate of 8*(m). Therefore we can apply the routines in 
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popular statistical packages such as SAS, SPSS and GLIM to estimate 0*(m) for a specific m and 
we can embed them in a program for seeking n? by numerically solving S2 = 0. Finally, we can 
obtain an estimate of B by taking a transformation from the LS estimate of 8'. 
We can estimate the scale parameter z by the moment method as mean square error; that is, 
Based on the proposition of Zeger and Qaqish,' we can calculate approximate 95 per cent 
confidence intervals for q = (0, m). Under some weak conditions, ,/N,(ij - q) converges to 
a Gaussian random vector with mean 0 and variance C, here N ,  = ni .  We can estimate the 
asymptotic variance of i j  by replacing q with its estimate in the following formula 
z =  A (ES\S1 ES\S2)-l 
ESzSl ESZ (9) 
When we specify parameters m and 8 and we have an initial value yo, we may generate a time 
series by calculating f k + = E(  Yk + I 9,) = 9, + G(fk; 8, m) for k = 0,1, . . . , to describe the 
average functional change over time. We can then estimate typical time t ,  to a certain value of 
Y from the curve. Therefore we can make predictions about future change. We can estimate the 
point Y ,  associated with maximum rate of change, if it exists, either from the curve or by formula 
(4). Since Y, is a function of parameters ao, cxl and m, when the variance of the parameter estimates 
are available, we can calculate a standard error of estimate f ,  by the well known delta method; 
approximate 95 per cent confidence intervals are simply 9, f 1-96 s.e.( ?J. In the case that a. and 
cxl are known, for 0 < m # 1, 
We can obtain an estimate of s.e. (F,) by replacing m with its estimate. 
2.3. Extended model 
When previous studies suggest a potential predictor of rapid progression of a disease, it is 
important to understand further its role in the disease course and describe its effect on functional 
decline. Let X denote a risk factor that may have an impact on a patient's functional process 
Y(T). We can extend the basic growth model to include X so that we can assess its effect on the 
shape of the curve. 
We can establish the extension in a flexible way, since the first moment 
E(AkI Yk, X) = G(Yk, X) can take various forms. For example, to test the effect of X on the rate of 
change, we may consider the model 
G(Yk, x; Y, 8, m) = R ( X ;  Y) G(Yk; 8, m) (10) 
where G(Yk;  8, m) is the basic model defined by (3), and the function R ( X ;  y )  reflects the relative 
rate of change due to X .  Taking a commonly used simple form, R ( X ;  y )  = exp(yX), we can 
interpret y as a relative rate of functional change caused by the increase of a unit of X .  When X is 
a binary variable that takes values of 0 or 1, exp(y) is the ratio of the conditional average change 
in the two groups indicated by X .  In principle, X can be in vector form. The extension of the 
model is straightforward. 
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Table I. Estimated model parameters (sue.) and 95 per cent 
confidence intervals for a basic model of mMMS progression, 
and an extended model that incorporates age at onset as 
a covariate. 
Parameter Basic model Ex tended model 
- 0.1724 (0.0210) - 0‘1629 (0.0221) 
( - 0.2062, - 0-1247) ( - 0.2118, - 0.1330) 
B 
m 0.8631 (0.2943) 1.1317 (0.3434) 
(0.2863, 1.4399) (0.4586, 1.8048) 
Y 0.3466 (0.1 132) 
(0.1247, 0.5685) 
7 23.8197 23.4572 
We can also treat X as a time dependent variable. Let X ( T )  denote an independent process 
that interferes with Y ( T ) ,  then E(Akl Yk, x k )  = G ( Y k ,  Xk; y, 8, m). In this case, we can still use the 
above models by replacing X with x k .  
3. APPLICATION 
We obtained the data from a multi-centre study of disease course in Alzheimer’s disease. The 
Predictors Study6 has followed a cohort of 236 patients with probable Alzheimer’s disease from 
New York, Baltimore and Boston for up to four years. The broad objective of the study is to 
develop a predictor model of the natural history of Alzheimer’s disease. Patients were recruited in 
the early stage of the disease, and underwent neurological, neuropsychological, psychiatric and 
functional assessments at  baseline and at repeated six-month intervals. 
A modified Mini-Mental State Examination (mMMS) was used to measure patients’ global 
intellectual function. The maximum score is 57, indicating normal cognitive ability, and minimum 
score is 0, indicating total loss of cognitive ability. Previous studies have suggested that a patient’s 
score initially remains relatively stable at  the higher level, then declines continuously until 
reaching another period of stability, with no further decline detectable.’.’ We have observed 
a similar phenomenon in our data set in which there were 1049 mMMS test scores available on 
218 subjects who had completed at least two consecutive visits and had been followed for 6 to 54 
months. Observed scores ranged from 0 to 57. The change between two consecutive visits ranged 
from -29 to 8. Patients with higher mMMS test scores at baseline tended to have smaller 
declines, while patients with lower test scores seemed to decline faster. Those patients with zero 
scores were experiencing the last stage of the disease, since a period of stable minimum score was 
often followed by death. These observations encouraged us to apply a basic growth model to the 
mMMS test scores. The average conditional change in the six month interval is described by (3) 
with ct0 = 0 and a, = 57. Estimated parameters of the basic model appear in Table I. 
The estimate of p is negative, indicating a decline in the test score. The estimate of the power 
parameter m is close to 1, suggesting that the pattern of decline is similar to a Gompertz model. 
The parameter z, which characterizes the conditional variance of the changes, is also the variance 
of residuals as defined in Section 2.2. Taking its square root, we have the standard deviation of 
residuals; 4.88 is the estimate for the basic model. 
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Figure 2. Conditional average change of mMMS score over six-month interval in 218 Alzheimer’s disease patients 
For each given score, we calculated the associated conditional average changes in a six-month 
interval by two methods: one is based on the model, the other is simply the mean of the observed 
changes. Figure 2 demonstrates that the smooth curve generated from the model seems to fit the 
empirical estimates fairly. The latter fluctuate markedly on the low and high given scores for 
which there are very few observations available. We can see from the curve that as the score 
decreases, the amount of decline gradually increases until the score drops to about 19 ( Y ,  = 19.4, 
95 per cent CI: 126-26.3), then it converges to zero as the score reaches its minimum. The pattern 
is compatible with that noted in another cohort study where the annual decline rates of MMS 
scores were displayed as a function of the average scores during the observation period.2 
Taking an initial value yo = 56, we use the model to generate a curve of mMMS scores 
(Figure 3). From the curve we may roughly estimate the period of decline as about 15 years. 
There is no pattern on the residual versus score plot (Figure 4), and 95 per cent of residuals for 
the basic model are within two standard deviations from mean zero, indicating that the basic 
model fits the data well. Although the model explains the majority of the data, the fact that there 
are some large residuals indicates some unexplained rapid decline and suggests that further 
application of the extended model to introduce other predictor variables may be useful. 
Previous studies have suggested that early onset of Alzheimer’s disease (before age 65) is 
characterized by faster clinical progression and is associated with decreased relative survival. 
Recently Jacobs et al.’ provided some longitudinal evidence of more rapid cognitive decline in 
patients with early onset of Alzheimer’s disease. They compared the rate of decline in cognitive 
measures including mMMS scores for patients in early and late onset groups who had compara- 
ble scores at baseline and were followed for two years. We used our model to study further the 
difference in the rate of cognitive decline between early and late onset groups across the entire 
disease span. 
There were 678 mMMS test scores available for 141 subjects in the late onset group and 361 
scores for 74 subjects in the early onset group. We first fit the basic model to the two groups’ data 
separately. We rejected the null hypothesis that the two groups follow the same process 
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Figure 4. Residual versus score plot 
(xz = 6.77, d.f. = 2, p = 0.03). We did not, however, reject the null hypothesis of equal power 
parameter (m in formula (3)) in the two groups (x2  = 1.88, d.f. = I, p = 0.17). This suggested 
consideration of an extended model such as (lo), where we treat X as an indicator variable, 1 for 
the early onset group and 0 for the late onset group. Estimated parameters for this extended 
model appear in Table I. It is clear that the decline pattern is similar in both groups since the 
estimate of j? is negative and they share the same power parameter. The estimate of y is positive 
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and significantly different from zero (p < 0.05). This indicates that for each given score, the 
average conditional change of mMMS scores over a six-month interval in the early onset group is 
larger than that in the late onset group. The rate of decline in the early onset group is 
exp(9) = 1.414 (95 per cent CI: 1.133-1.765) times that in the late onset group. This implies more 
rapid progression and shorter disease course in the early onset group. 
The estimate of scale parameter z in the extended model is smaller than that in the basic model. 
Estimated standard deviation of residuals from the extended model is 4.84. In the residual versus 
score plot (Figure 4), although the range of spread is similar, the residuals from the extended 
model are more condensed than those from the basic model, indicating that the extended model 
fits the data better. There are still a few ‘outliers’ that the extended model (10) with the single 
factor of early onset does not explain. The large residuals suggest the utility of exploration of the 
effects of additional factors that also may relate to decline. 
Note that in Table I the power parameter rn in both models has an estimated value close to 1, 
suggesting a simplification of the models by taking rn = 1. 
4. DISCUSSION 
This paper proposes a method for modelling functional decline patterns, and investigating the 
effect of possible predictors on these patterns. The presented example of progression of 
Alzheimer’s disease demonstrates the potential utility of this technique. 
The proposed method requires several assumptions. First, the basic model assumes that all 
patients follow the same underlying functional process in disease progression. This means that 
each subject’s functional measures during the follow-up period are a piece of the realization of this 
process. Patients, however, are not homogenous and they may have different characteristics that 
may influence disease progression. The better a model reflects an individual subject’s specific 
pattern of functional decline, the more realistic it is. It would also be more helpful in counselling 
about disease prognosis. The application of the extended model to patients with specific predictor 
profiles (for example, early versus late onset) is an initial step, since it can tailor the model better 
to an individual patient. Still, a model that takes into account subject-specific variations in 
measures over time is useful although more challenging to develop. To meet this goal, we need 
further studies of subject-specific patterns of functional decline. 
The second required assumption for the modelling technique is that the observed functional 
measures from all the patients in the follow-up study collectively span the entire disease course. 
To satisfy this assumption, one should recruit into the study patients both in the beginning or 
very early stage and in the moderate to late stages of the disease; furthermore, the follow-up 
period should have sufficient length. 
The current method applies only to data collected on consecutive visits with a constant time 
interval. Since missing data (due to absence on scheduled visits or uncompleted tests) may reduce 
the power of the method, it would be useful to have further development of a non-linear time 
series model that takes into account missing data. Alternatively, there should be development of 
a method for modelling functional decline for data with length-varied time intervals. 
ACKNOWLEDGEMENTS 
This research was supported by grant T32-MH19139-05 from the National Institute for 
Mental Health, grant NIAID-5-R29-AI29004-02 from the National Institutes of Health, 
Federal grant AGO7370 and the Charles S. Robertson Gift for Alzheimer’s Disease from the 
Banbury Fund. 
1032 X. LIU. W-Y. TSAI AND Y. STERN 
REFERENCES 
1. Brooks, J., Kraemer, H. C., Tanke, E. D. and Yesavage, J. A. ‘The methodology of studying decline in 
Alzheimer’s disease’, Journal of American Geriatrics Society, 41, 623-628 (1993). 
2. Morris, J. C., Edland, S., Clark, C., Galasko, D., Koss, E., Mohs, R., Belle, G. van, Fillenbaum, G. and 
Heyman, A. ‘The consortium to establish a registry for Alzheimer’s disease (CERAD). Part IV. Rate of 
cognitive change in the longitudinal assessment of probable Alzheimer’s disease’, Neurology, 43, 
2457-2465 (1993). 
3. Draper, N. and Smith, H. Applied Regression Analysis, 2nd edn. Wiley, New York, 1981. 
4. Godambe, V. P. ‘The foundations of finite sample estimation in stochastic processes’, Biornetrics, 72, 
419428 (1985). 
5. Zeger, S. L. and Qaqish, B. ‘Markov regression models for time series: A quasi-likelihood approach’, 
Biornetrics, 44, 1019-1031 (1988). 
6. Stern, Y., Folstein, M., Richards, M., Miller, L., Bylsma, F., Lafleche, G., Marder, K., Bell, K., Sano, M., 
Devanand, D., Loreck, D., Wootten, J. and Bello, J. ‘Multicenter study of predictors of disease course in 
Alzheimer’s disease (the “Predictors study”). I. Study design, cohort description, and intersite compari- 
sons’, Alzheimer Disease and Associated Disorders, 7 ,  3-21 (1993). 
7. Jacobs, D., Sano, M., Marder, K., Bell, K., Bylsma, F., Lafleche, G., Albert, M., Brabdt, J. and Stern, Y. 
‘Age of onset of Alzheimer’s disease: Relation to pattern of cognitive dysfunction and rate of decline’, 
Neurology, 44, 1215-1220 (1994). 
